165
Views
7
CrossRef citations to date
0
Altmetric
Original Articles

Comparing Characteristics of Early-Onset Injection Drug Users to Those With Late-Onset Injection in Kermanshah, Iran

, , , , , , , , , , , & show all

References

  • Abelson, J., Treloar, C., Crawford, J., Kippax, S., Van Beek, I., & Howard, J. (2006). Some characteristics of early‐onset injection drug users prior to and at the time of their first injection. Addiction, 101(4), 548–555.
  • Arreola, S., Bluthenthal, R. N., Wenger, L., Chu, D., Thing, J., & Kral, A. H. (2014). Characteristics of people who initiate injection drug use later in life. Drug and Alcohol Dependence, 138, 244–250.
  • Battjes, R. J., Leukefeld, C. G., & Pickens, R. W. (1992). Age at first injection and HIV risk among intravenous drug users. The American Journal of Drug and Alcohol Abuse, 18(3), 263–273.
  • Broz, D., Pham, H., Spiller, M., Wejnert, C., Le, B., Neaigus, A., & Paz-Bailey, G. (2014). Prevalence of HIV infection and risk behaviors among younger and older injecting drug users in the United States, 2009. AIDS and Behavior, 18(3), 284–296.
  • Bryant, J., & Treloar, C. (2008). Initiators: An examination of young injecting drug users who initiate others to injecting. AIDS and Behavior, 12(6), 885–890.
  • Buxton, M. B., Vlahov, D., Strathdee, S. A., Des Jarlais, D. C., Morse, E. V., Ouellet, L., & Garfein, R. S. (2004). Association between injection practices and duration of injection among recently initiated injection drug users. Drug and Alcohol Dependence, 75(2), 177–183.
  • Carneiro, M., Fuller, C., Doherty, M. C., & Vlahov, D. (1999). HIV prevalence and risk behaviors among new initiates into injection drug use over the age of 40 sources old. Drug and Alcohol Dependence, 54(1), 83–86.
  • Crofts, N., Louie, R., Rosenthal, D., & Jolley, D. (1996). The first hit: Circumstances surrounding initiation into injecting. Addiction, 91(8), 1187–1196.
  • Day, C. A., Ross, J., Dietze, P., & Dolan, K. (2005). Initiation to heroin injecting among heroin users in Sydney, Australia: Cross sectional survey. Harm Reduction Journal, 2(1), 2.
  • Fuller, C. M., Vlahov, D., Arria, A. M., Ompad, D. C., Garfein, R., & Strathdee, S. A. (2001). Factors associated with adolescent initiation of injection drug use. Public Health Reports, 116(Suppl 1), 136–145.
  • Garten, R. J., Lai, S., Zhang, J., Liu, W., Chen, J., Vlahov, D., & Yu, X.-F. (2004). Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. International Journal of Epidemiology, 33(1), 182–188.
  • Hagan, H., Pouget, E. R., Des Jarlais, D. C., & Lelutiu-Weinberger, C. (2008). Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. American Journal of Epidemiology, 168(10), 1099–1109.
  • Horyniak, D., Dietze, P., Degenhardt, L., Higgs, P., McIlwraith, F., Alati, R., & Burns, L. (2013). The relationship between age and risky injecting behaviours among a sample of Australian people who inject drugs. Drug and Alcohol Dependence, 132(3), 541–546.
  • Kandel, D. B., Yamaguchi, K., & Chen, K. (1992). Stages of progression in drug involvement from adolescence to adulthood: Further evidence for the gateway theory. Journal of Studies on Alcohol, 53(5), 447–457.
  • Kral, A. H., Bluthenthal, R. N., Lorvick, J., Gee, L., Bacchetti, P., & Edlin, B. R. (2001). Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: Risk-factor analysis. The Lancet, 357(9266), 1397–1401.
  • Kral, A. H., Lorvick, J., & Edlin, B. R. (2000). Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco. JAIDS Journal of Acquired Immune Deficiency Syndromes, 24(2), 162–167.
  • Lankenau, S. E., Teti, M., Silva, K., Bloom, J. J., Harocopos, A., & Treese, M. (2012). Initiation into prescription opioid misuse amongst young injection drug users. International Journal of Drug Policy, 23(1), 37–44.
  • Latkin, C. A., & Vlahov, D. (1998). Socially desirable response tendency as a correlate of accuracy of self‐reported HIV serostatus for HIV seropositive injection drug users. Addiction, 93(8), 1191–1197.
  • Loxley, W. M., Phillips, M., Carruthers, S. J., & Bevan, J. S. (1997). The Australian study of HIV and injecting drug use. Part I: Prevalence for HIV, hepatitis B and hepatitis C among injecting drug users in four Australian cities. Drug and Alcohol Review, 16(3), 207–214.
  • Marshall, B. D., Wood, E., Shoveller, J. A., Buxton, J. A., Montaner, J. S., & Kerr, T. (2011). Individual, social, and environmental factors associated with initiating methamphetamine injection: Implications for drug use and HIV prevention strategies. Prevention Science, 12(2), 173–180.
  • Miller, C. L., Pearce, M. E., Moniruzzaman, A., Thomas, V., Christian, C. W., Schechter, M. T., & Spittal, P. M. (2011). The Cedar project: Risk factors for transition to injection drug use among young, urban Aboriginal people. Canadian Medical Association Journal, 183(10), 1147–1154.
  • Miller, C. L., Strathdee, S. A., Kerr, T., Li, K., & Wood, E. (2006). Factors associated with early adolescent initiation into injection drug use: Implications for intervention programs. Journal of Adolescent Health, 38(4), 462–464.
  • Mirahmadizadeh, A., Majdzadeh, R., Mohammad, K., & Forouzanfar, M. (2009). Prevalence of HIV and hepatitis C virus infections and related behavioral determinants among injecting drug users of drop-in centers in Iran. Iranian Red Crescent Medical Journal, 11(3), 325.
  • Molitor, F., Ruiz, J. D., Flynn, N., Mikanda, J. N., Sun, R. K., & Anderson, R. (1999). Methamphetamine use and sexual and injection risk behaviors among out-of-treatment injection drug users. The American Journal of Drug and Alcohol Abuse, 25(3), 475–493.
  • National AIDS Committee Secretariat & Ministry of Health and Medical Education. (2015). Islamic Republic of Iran AIDS progress report: On monitoring of the United Nations General Assembly Special Session on HIV and AIDS. Tehran, Iran: Jangal.
  • Noroozi, A., Mirzazadeh, A., Hajebi, A., Farhoudian, A., Sharifi, H., Higgs, P., & Noroozi, M. (2016). Comparing profile of people who inject drugs (PWID) accessing different types of needle and syringe programs or secondary distribution in Kermanshah, Iran. Journal of Substance Use. Advance online publication. doi:10.1080/14659891.2016.1195894
  • Noroozi, M., Mirzazadeh, A., Noroozi, A., Mehrabi, Y., Hajebi, A., Zamani, S., & Soori, H. (2015). Client-level coverage of needle and syringe program and high-risk injection behaviors: A case study of people who inject drugs in Kermanshah, Iran. Addiction and Health, 7(3–4), 164–173.
  • Noroozi, M. M., Nejat, S., Golestan, B., & Majdzadeh, R. (2012). What are differences between non-injecting and injecting drug addicts? International Journal of Preventive Medicine, 3(6), 414–419.
  • Rahimi-Movaghar, A., Amin-Esmaeili, M., Haghdoost, A.-A., Sadeghirad, B., & Mohraz, M. (2012). HIV prevalence amongst injecting drug users in Iran: A systematic review of studies conducted during the decade 1998–2007. International Journal of Drug Policy, 23(4), 271–278.
  • Roy, É., Nonn, É., & Haley, N. (2008). Transition to injection drug use among street youth—A qualitative analysis. Drug and Alcohol Dependence, 94(1), 19–29.
  • Salazar, L. F., Crosby, R. A., Holtgrave, D. R., Head, S., Hadsock, B., Todd, J., & Shouse, R. L. (2007). Homelessness and HIV-associated risk behavior among African American men who inject drugs and reside in the urban south of the United States. AIDS and Behavior, 11(2), 70–77.
  • Sanchez, J., Page, J., Chitwood, D., McBride, D., Kitner, K., & Comerford, M. (2000). First injection and current risk factors for HIV among new and long-term injection drug users. AIDS Care, 12(3), 313–320.
  • Vazirian, M., Nassirimanesh, B., Zamani, S., Ono-Kihara, M., Kihara, M., Ravari, S. M., & Gouya, M. M. (2005). Needle and syringe sharing practices of injecting drug users participating in an outreach HIV prevention program in Tehran, Iran: A cross-sectional study. Harm Reduction Journal, 2(1), 19.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.